Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04318938
Other study ID # ABP
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date March 30, 2020
Est. completion date December 31, 2025

Study information

Verified date August 2023
Source Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, randomized, open-label, multicenter phase II study investigating the advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping


Description:

The aim of this study is to compare efficacy of brigatinib and other 2nd-generation ALK tyrosin kinase inhibitor (TKI) in 1st and 2nd line treatment and to explore resistance patterns according to treatment and molecular properties of the tumors


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 118
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Fully informed written consent and any locally-required authorization (EU Data Privacy Directive) given by the patient 2. Male or female = 18 years of age NOTE: There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently. 3. Histologically confirmed locally advanced (stage III) and not suitable for curative treatment, i.e. R0 operation or definitive chemo-/radiation, or metastatic (stage IV) ALK+ NSCLC NOTE: Documentation of ALK rearrangement by a positive result of any ALK assay approved in Germany [i.e. positivity for at least one of the three: immunohistochemistry (IHC), NGS, fluorescence in situ hybridisation (FISH)] must be available at baseline. Treatment can already be started based on a local ALK+ test result, but subsequent central testing of the baseline biopsy for molecular profiling, incl. determination of ALK variant and TP53 status, should be made possible for all patients. 4. No prior therapy for metastatic ALK+ NSCLC including therapy with ALK inhibitors. However, 1 or 2 cycles of chemotherapy, chemo-immunotherapy or immunotherapy as well as cerebral irradiation before inclusion in the study will be allowed. 5. At least 1 measurable (i.e., target) lesion per RECIST v1.1 or otherwise evaluable lesion (e.g. brain lesion with at least 5 mm of longest diameter if measured by high-resolution cMRT e.g. using 1 mm slices thickness and not planned for irradiation before the first response assessment). 6. Eastern Cooperative Oncology Group (ECOG) performance status = 2 7. Have adequate organ function, as determined by: - Total bilirubin =1.5x the upper limit of the normal range (ULN) (< 3x the ULN if Gilbert's disease is present) - Estimated glomerular filtration rate =30 mL/minute/1.73 m2 (calculated by Modification of Diet in Renal Disease (MDRD) or any other validated formula, see Appendix 13.4) - Alanine aminotransferase/aspartate aminotransferase =2.5x ULN NOTE: =5x ULN is acceptable if liver metastases are present. - Serum lipase or serum amylase = 1.5x ULN - Platelet count =75x 109/L - Hemoglobin =9 g/dL - Absolute neutrophil count =1.5x 109/L 8. Willingness and ability to comply with scheduled visit and study procedures 9. Patient willing to participate in accompanying research program 10. Collection of current biopsy during screening must be feasible NOTE: For each patient a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block must be available for biomarker evaluation. Excisional, incisional or core needle biopsies are appropriate, while fine needle aspirations are insufficient. 11. Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days prior to randomization. Women must not be breastfeeding. 12. Female patients who: - are postmenopausal for at least 1 year before the screening visit, OR - are surgically sterile, OR - if they are of childbearing potential, agree to practice highly effective non-hormonal contraception from the time of signing the informed consent through at least 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse. Male patients, even if surgically sterilized (i.e., status post-vasectomy), who: - agree to practice effective barrier contraception during the entire study treatment period and through at least 3 months after the last dose of study drug, OR - agree to completely abstain from heterosexual intercourse. Exclusion Criteria: 1. History or presence at baseline of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis 2. Uncontrolled hypertension, defined as hypertension treated* with anti-hypertensive drugs AND blood pressure = 160 mmHg (systolic) or = 100 mmHg (diastolic) in repeated measurements. Untreated elevated blood pressure is not an exclusion criterion and should receive adequate anti-hypertensive adjustment. *Please notecase of treatment, at least 3 anti-hypertensive drugs should have been used with the intention to control hypertensive disease 3. Systemic treatment with strong cytochrome P-450 (CYP) 3A inhibitors, strong CYP3A inducers, or moderate CYP3A inducers or treatment with any investigational systemic anticancer agents, chemotherapy or radiation therapy (except for stereotactic radiosurgery or stereotactic radiation therapy or palliative radiotherapy) within 14 days of randomization 4. Treatment with antineoplastic monoclonal antibodies within 30 days of randomization 5. Major surgery within 30 days of randomization. Minor surgical procedures, such as catheter placement or minimally invasive biopsies, are allowed. 6. Current symptomatic spinal cord compression as confirmed by radiographic imaging. Patients with leptomeningeal disease without symptomatic cord compression are allowed. 7. Significant or uncontrolled cardiovascular disease, defined as to the following: - If an acute myocardial infarction has ensued in the past 6 months, successful reperfusion has to be documented and the patient has to be free of symptoms - New York Heart Association Class III or IV heart failure (i.e. marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest) within 6 months prior to randomization - Any history of clinically significant ventricular arrhythmia, defined as ventricular tachycardia (VT), ventricular fibrillation (VF), or cardiac arrest 8. Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose of study drug 9. Malabsorption syndrome or other gastrointestinal illness or condition that could affect oral absorption of the study drug 10. Active severe or uncontrolled chronic infection, including but not limited to, the requirement for intravenous antibiotics for longer than 2 weeks 11. History of HIV infection. Testing is not required in the absence of history. 12. Chronic hepatitis B (surface antigen-positive) or chronic active hepatitis C infection. Testing is not required in the absence of history. 13. Any serious medical condition or psychiatric illness that could, in the investigator's opinion, potentially compromise patient safety or interfere with the completion of treatment according to this protocol 14. Known or suspected hypersensitivity to brigatinib or other TKI or their excipients 15. Life-threatening illness unrelated to cancer 16. Involvement in the planning and/or conduct of the study (applies to both Takeda staff and/or staff of sponsor and study site) 17. Patient who might be dependent on the sponsor, site or the investigator 18. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities [according to national Medicinal Products Act (Arzneimittelgesetz, AMG)] 19. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [according to national AMG] 20. Legal incapacity or limited legal capacity 21. Females who are pregnant or breastfeeding 22. Patients who have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening or asymptomatic disease requiring an increasing dose of corticosteroids to control symptoms within 7 days prior to randomization. NOTE: If a patient has worsening neurological symptoms or signs due to CNS metastasis, the patient needs to complete local therapy and be neurologically stable (with no requirement for an increasing dose of corticosteroids or use of anticonvulsants) for 7 days prior to randomization. 23. Rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Brigatinib
Treatment with Brigatinib
Tyrosine kinase inhibitor
Treatment with any TKI

Locations

Country Name City State
Germany Charité Berlin Berlin
Germany HELIOS Klinikum Emil von Behring Berlin
Germany Universitätsmedizin Essen Essen
Germany Klinikum Esslingen Esslingen
Germany Krankenhaus Nordwest Frankfurt Frankfurt am main
Germany Universitätsklinikum Freiburg Freiburg
Germany Niels-Stensen-Kliniken Georgsmarienhütte Georgsmarienhütte
Germany Universitätsklinikum Gießen Gießen
Germany Studiengesellschaft Hämato-Onkologie Hamburg Hamburg
Germany Evangelisches Krankenhaus Hamm Hamm
Germany KRH Klinikum Siloah Hannover Hannover
Germany Medizinische Hochschule Hannover Hannover
Germany Thoraxklinik am Universitätsklinikum Heidelberg Heidelberg
Germany Lungenklinik Hemer Hemer
Germany Universitätsklinikum Jena Jena
Germany Lungenklinik Köln - Merheim Köln
Germany Universitätsklinikum Leipzig Leipzig
Germany Universitätsmedizin Mainz Mainz
Germany Klinik der LMU München - Innenstadt München
Germany Universitätsklinikum Münster Münster
Germany Klinikum Nürnberg Nürnberg
Germany Pius Hospital Oldenburg Oldenburg
Germany Universitätsklinikum Regensburg Regensburg
Germany Klinik Schillerhöhe Stuttgart
Germany Universitätsklinikum Ulm Ulm
Germany Universitätsklinikum Würzburg Würzburg

Sponsors (1)

Lead Sponsor Collaborator
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other ALK variant analysis in tumor tissue Typing of ALK fusion variants in tumor samples 68 months
Other ALK variant analysis in blood samples Typing of ALK fusion variants in blood samples 68 months
Other TP53 mutation status in tumor tissue Assessment of TP53 mutation status in tumor samples 68 months
Other TP53 mutation status in blood samples Assessment of TP53 mutation status in blood samples 68 months
Other Detection of "acquired resistance" mutations in tumor tissue Detection of "acquired resistance" mutations via standardized next-generation sequencing (NGS)-based multiplex analysis in tumor samples 68 months
Other Detection of "acquired resistance" mutations in blood samples Detection of "acquired resistance" mutations via standardized next-generation sequencing (NGS)-based multiplex analysis in blood samples 68 months
Other ALK variant analysis in cerebrospinal fluid Typing of ALK fusion variants in cerebrospinal fluid in "brain-only" progression. 68 months
Other TP53 mutation status in cerebrospinal fluid Assessment of TP53 mutation status in cerebrospinal fluid in "brain-only" progression. 68 months
Other Detection of "acquired resistance" mutations in cerebrospinal fluid Detection of "acquired resistance" mutations via standardized circulating tumor DNA (ctDNA) next-generation sequencing (NGS)-based multiplex analysis in cerebrospinal fluid 68 months
Primary Progression-free survival (PFS) of 1st-line treatment according to RECIST v1.1 Time from the first dosing date of any study medication to the date of the first objectively documented tumor progression or death due to any cause 68 months
Secondary PFS of 2nd-line treatment according to RECIST v1.1 Time from the first dosing date of any 2nd-line TKI to the date of the objectively documented tumor progression or death due to any cause 68 months
Secondary TNT 1st line (TNT1, i.e. time-to-next treatment for the 1st line) Time from begin of 1st-line treatment until begin of 2nd-line treatment 68 months
Secondary TNT 2nd line (TNT2, i.e. time-to-next treatment for the 2nd line Time from begin of 2nd line until begin of 3rd-line treatment 68 months
Secondary TNT1/2 (time-to-next treatment for the 1st and 2nd line together) Time from begin of 1st-line treatment until begin of 3rd-line treatment 68 months
Secondary Overall survival (OS) Time from treatment start in the 1st line to the date of death (due to any cause) 68 months
Secondary Intracranial ORR (iORR) Percentage of participants with a best overall intracranial response (BOR) of intracranial complete response (CR) or intracranial partial response (PR). Best overall intracranial response (BOR) is defined as the best response designation, recorded between the date of first dose and the date of the initial objectively documented intracranial tumor progression per RECIST criteria or the date of subsequent therapy or death, whichever occurs first. 68 months
Secondary Intracranial DOR (iDOR) according to RECIST v1.1 Time from first documentation of intracranial CR or PR according to RECIST v1.1 (whichever is first recorded) until the first date that the intracranial progressive disease (PD) is objectively documented or until death (whichever occurs first 68 months
Secondary Time to intracranial progression (TTiP) Time from start of 1st-line treatment until the occurrence of a new central nervous system (CNS) lesion or progression of pre-existing CNS lesions 68 months
Secondary Safety (rate of adverse events) Type, incidence and severity of adverse events (AEs) and serious adverse events (SAEs)graded according to NCI CTCAE v5.0 68 months
Secondary Quality of life (QoL) assessed by SF-12-questionnaire Patient reported outcome assessed by the validated SF-12-questionnaire 68 months
Secondary Quality of life (QoL) assessed by EORTC-quality of life questionnaire (QLQ)-BN20-questionnaire Patient reported outcome assessed by the validated EORTC-QLQ-BN20-questionnaire 68 months
See also
  Status Clinical Trial Phase
Recruiting NCT05821933 - RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC Phase 1/Phase 2
Active, not recruiting NCT03269162 - Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection Phase 3
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT06315686 - The Dynamic Monitoring of Cerebrospinal Fluid ctDNA Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Recruiting NCT05466149 - Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT03609918 - Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Recruiting NCT06043817 - First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT05078931 - A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients Phase 2
Not yet recruiting NCT05547737 - Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Withdrawn NCT05959473 - EGFR_IUO 3.20 Clinical Study Protocol N/A
Not yet recruiting NCT05005468 - A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. Phase 2
Recruiting NCT01690390 - Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease Phase 2
Completed NCT01852578 - Cabazitaxel in Relapsed and Metastatic NSCLC Phase 2
Active, not recruiting NCT01460472 - Immunotherapy With Racotumomab in Advanced Lung Cancer Phase 3
Completed NCT00702975 - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy Phase 2
Completed NCT00866970 - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia Phase 2